August 23, 2022
United States Securities and Exchange Commission
Division of Corporation Finance
100 F Street, N.E.
Washington, D.C. 20549
CTI BioPharma Corp.
Registration Statement on Form S-3 (File No. 333-266926)
To Whom it May Concern:
Pursuant to Rule 461 under the Securities Act of 1933, as amended (the Act), CTI BioPharma Corp. (the Company) hereby requests that the effective date of the above-referenced registration statement (the Registration Statement) be accelerated to August 25, 2022, at 4:00 p.m., Eastern Time, or as soon thereafter as practicable, unless we or our outside counsel request by telephone that such Registration Statement be declared effective at some other time.
Once the Registration Statement is effective, please confirm the event with our counsel, Gibson, Dunn & Crutcher LLP by calling Branden C. Berns at (917) 302-4510 or emailing email@example.com.
|CTI BioPharma Corp.|
|Chief Financial Officer|
Ryan A. Murr, Gibson, Dunn & Crutcher LLP
Branden C. Berns, Gibson, Dunn & Crutcher LLP